Skip to content
Screener

Evolus EOLS Business Segments — Interest Income

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — Interest Income
$2.5M+400%
Bicara Therapeutics logo
BCAXReportable Segment — Interest Income
$4.08M-18.6%
nCino, Inc. logo
NCNOReportable Segment — Interest Income
$366K-12.2%
DocuSign logo
DOCUReportable Segment — Interest Income
$8.73M-18.4%
UiPath logo
PATHReportable Segment — Interest Income
$10.4M-17.8%
YSS
YSSReportable Segment — Interest Income
$4.62M+754%

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Cash & equivalents$45.2M-26.8%
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$500M+31.0%
Enterprise value$619.64M+32.8%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.

The source filing: Evolus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:56 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053468
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development1,8921,8374,1324,049
Selling, general and administrative57,05256,675109,033113,315
Depreciation and amortization1,5299323,0671,756
Interest income(296)(479)(581)(1,189)
Interest expense4,1727,2078,14711,622
Income tax (benefit) expense(154)53102125
Other segment items(1)1,037(3,763)903(1,669)
Segment net loss$(8,052)$(17,142)$(18,726)$(36,034)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Evolus's business segments — interest income?
Evolus (EOLS) reported business segments — interest income of $296K in Q2 2026.
How has Evolus's business segments — interest income changed year-over-year?
Evolus's business segments — interest income decreased by 38.2% year-over-year, from $479K to $296K.
What is the long-term trend for Evolus's business segments — interest income?
Over 3 years (2022 to 2025), Evolus's business segments — interest income has grown at a 153.2% compound annual growth rate (CAGR), from $119K to $1.93M.
What does business segments — interest income mean?
Reflects the income earned by the segment from cash balances, short-term investments, or other interest-bearing assets. It indicates the segment's ability to generate returns on its available liquid capital.

Ask your AI about Evolus's business segments — interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude